Skip to main content

Panelists discuss how long-term data from the Clarity AD OLE study support lecanemab as an effective maintenance therapy for early Alzheimer’s disease, with reduced infusion frequency improving patient and caregiver quality of life, while potentially delaying disease progression and enhancing long-term cognitive and functional outcomes.:

Source: Neurology Read More